这项研究发现指出了提高癌症疗法效果的新途径，提升了CAR-T细胞疗法治疗血液癌症（如淋巴瘤和白血病）的可能性。改进后的CAR-T细胞不仅能更好地抵御肿瘤，还能在体内保持长期活性，从而降低癌症复发的风险。目前，研究人员正在探索是否可以用相同的基因修饰方 ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

毛建华团队的初步研究凸显了CAR-T疗法作为儿童难治性系统性红斑狼疮潜在治疗方案的潜力。然而，目前国内外CAR-T疗法在治疗自身免疫性疾病方面尚未形成明确的规范和指南，仍处于临床试验阶段。考虑到儿童与成人在生理和免疫系统上的差异，儿童CAR-T疗法在 ...

Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the ...

CAR-T cell therapy achieves 18-year survival milestone in cancer patient Innovative cancer treatment shows promise as ...

近日，陆道培医院陆佩华院长作为第一作者和通讯作者，在国际血液学权威期刊 Blood（IF = 21）在线发表了题为「Nanobody-based Naturally Selected CD7-Targeted Chimeric Antigen ...

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...

Laboratories International announced an agreement with Singapore General Hospital SGH to provide Current Good Manufacturing ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

The collaboration will drive cord blood-derived allogeneic CAR T-cell development. Singapore General Hospital (SGH) has ...

The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...